YIH
CTXR icon

Y-Intercept (HK)’s Citius Pharmaceuticals CTXR Stock Holding History

Y-Intercept (HK)’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,579
Closed -$227K – 1396
2024
Q2 		$227K Buy
+15,579
New +$279K 0.01% 1134
2023
Q2 		– Sell
-424
Closed -$12.4K – 1342
2023
Q1 		$12.4K Buy
+424
New +$12.2K ﹤0.01% 1130
2022
Q3 		– Sell
-694
Closed -$16K – 1022
2022
Q2 		$16K Buy
+694
New +$19K ﹤0.01% 798

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Y-Intercept (HK)'s CTXR Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 15,579 shares — an estimated $227K sold.

Y-Intercept (HK) first reported a position in CTXR in Q2 2022 and held it in 3 quarters. The position peaked at $227K in Q2 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 15,579 Citius Pharmaceuticals shares in Q3 2024, an estimated $227K.
  • Y-Intercept (HK) first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Y-Intercept (HK)'s Citius Pharmaceuticals position peaked at $227K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.